<DOC>
	<DOC>NCT00192712</DOC>
	<brief_summary>The study hypothesis is that chemoradiation based on 2 drugs will improve local control and long-term survival in patients with locally advanced pancreatic cancer. That is why gemcitabine and irinotecan are combined in an induction phase of 2 months and then this IrinoGem combination is given for 3 more cycles, in reduced doses,concurently with irradiation.</brief_summary>
	<brief_title>Irinotecan, Gemcitabine and Radiation Therapy for Pancreatic Cancer</brief_title>
	<detailed_description />
	<mesh_term>Pancreatic Neoplasms</mesh_term>
	<mesh_term>Gemcitabine</mesh_term>
	<mesh_term>Irinotecan</mesh_term>
	<mesh_term>Camptothecin</mesh_term>
	<criteria>locally advanced pancreatic cancer performance status 02 normal blood count and chemistry no previous chemotherapy or radiotherapy serious concurrent systemic disease</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2010</verification_date>
	<keyword>carcinoma</keyword>
	<keyword>pancreas</keyword>
	<keyword>chemotherapy</keyword>
	<keyword>radiotherapy</keyword>
</DOC>